International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety새로운 백신 물질에 대한 INN(International Nonproprietary Names): 안전성 문제Review Published on 2022-01-032022-09-11 Journal: Vaccine [Category] SARS, 변종, [키워드] applicability assigned Biological Biological Standardization Committee COVID-19 COVID-19 pandemic criteria ENhance exchange expert explain facilitate Health Organization inactivated information ingredient International Nonproprietary Names live-attenuated vaccine live-attenuated vaccines mRNA vaccines mRNA vaccines. name novel Novel vaccine substances novel vaccines nucleic acid nucleic acids patient safety pharmacovigilance recipients Recombinant protein recombinant proteins Safe SARS-CoV-2 SARS-CoV-2 vaccine the WHO Traditional unique Vaccine Vaccines Viral vector vaccines virus variant virus variants WHO World Health Organization [DOI] 10.1016/j.vaccine.2021.11.054 PMC 바로가기 [Article Type] Review
IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?IABS/CEPI 플랫폼 기술 웨비나: 백신 개발 시간 단축이 가능한가?Article Published on 2021-06-012022-08-31 Journal: Biologicals : journal of the International Associa [Category] MERS, SARS, 변종, 신약개발, [키워드] Alliance backbone Biological Biological Standardization Coalition component COVID-19 COVID-19 vaccine development disease Diseases Emerging infectious diseases faster Genetic Infectious diseases Innovation input joint meeting organized pandemic pathogen Pathogens platform Platform technology protein sequences rapid response reduce Regulatory Regulatory Authorities regulatory authority SARS-CoV-2 the vaccine Vaccine development Vaccine development. variants of SARS-CoV-2 [DOI] 10.1016/j.biologicals.2021.04.005 PMC 바로가기 [Article Type] Article
Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemicSARS-CoV-2의 바이러스학, 역학, 면역학 및 백신 개발, 대유행 9개월 만에 업데이트Meeting Report Published on 2021-01-012022-09-01 Journal: Biologicals : journal of the International Associa [Category] SARS, 신약개발, 임상, 진단, [키워드] Alliance antibody Biological Biological Standardization contribute country COVAX COVID-19 dose Epidemiology Highlights IgA immunology Initially International mucosal immune nasal Neutralizing antibodies nine organized pandemic public health emergency Recombination Saliva SARS-CoV-2 SARS-CoV-2 disease SARS-COV-2 infection second wave the vaccine Transmissibility Vaccine Vaccine development Virology virus [DOI] 10.1016/j.biologicals.2020.11.003 PMC 바로가기 [Article Type] Meeting Report